The American Society of Hematology recently released a new journal, Blood Advances. This journal is an online only open access journal, publishing articles on basic laboratory, translational, and clinical investigations in hematology. Topics cover all aspects of hemtology, including disorders of leukocytes, both benign and malignant, erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology.
Check out a few recent articles below:
Some interesting articles from the current issue:
Check out a few recent articles below:
Bergerson, R., Williams, R., Wang, H., Shanley, R., Colbenson, G., & Kerber, A. et al. (2016). Fewer circulating natural killer cells 28 days after double cord blood transplantation predicts inferior survival and IL-15 response. Blood Advances, 1(3), 208-218.Blood Advances joins the long running Blood. Established in 1946, Blood remains the most cited peer reviewed publication in the field of hematology. JCU has a subscription to Blood, so all JCU users have full text access to the full range of articles over the last 70 years. Published weekly, it should be the first stop for anyone studying hematology.
Quek, L., Ferguson, P., Metzner, M., Ahmed, I., Kennedy, A., & Garnett, C. et al. (2016). Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Advances, 1(3), 193-204.
Overholt, K., Rose, M., Joshi, S., Herman, G., Bajwa, R., & Abu-Arja, R. et al. (2016). Hematopoietic cell transplantation for a child with OSTM1 osteopetrosis. Blood Advances, 1(4), 279-281.
Some interesting articles from the current issue:
Carpenter, P. & Englund, J. (2016). How I vaccinate blood and marrow transplant recipients. Blood, 127(23), 2824-2832.So, what are you waiting for? Go check out Blood and Blood Advances today!
Girelli, D., Nemeth, E., & Swinkels, D. (2016). Hepcidin in the diagnosis of iron disorders. Blood, 127(23), 2809-2813.
Gorski, M., Blighe, K., Lotta, L., Pappalardo, E., Garagiola, I., & Mancini, I. et al. (2016). Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients. Blood, 127(23), 2924-2933.
Comments